Abstract
Background/objectiveFor obstructive sleep apnea (OSA) patients on continuous positive airway pressure (CPAP) treatment, the apnea-hypopnea index (AHI) is a key measure of treatment efficacy. However, the residual AHI is CPAP brand specific. Here, we studied changes in residual AHI in patients who used two different brands over their treatment history. Patients/methodsUsing our CPAP telemonitoring database of 3102 patients, we compared the residual AHI of 69 patients before and after change in their CPAP device. ResultsA paired Wilcoxon signed-rank test revealed a significant difference between brands in the reported AHI, which might be clinically misleading. ConclusionsThese findings suggest that physicians should be alerted to the differences between brands and learned societies should push for standardization of AHI reporting.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
